No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
KNSA240517C22500
- 0.12
- +0.02+20.00%
15min DelayTrading May 10 09:48 ET
0.12High0.09Low
0.10Open0.10Pre Close18 Volume58 Open Interest22.50Strike Price176.00Turnover76.20%IV15.35%PremiumMay 17, 2024Expiry Date0.00Intrinsic Value100Multiplier7DDays to Expiry0.12Time Value100Contract SizeAmericanOptions Type0.1193Delta0.0930Gamma163.42Leverage Ratio-0.0282Theta0.0005Rho19.50Eff Leverage0.0056Vega
Intraday
- 5D
- 1D
News
Market Underestimates Kiniksa Pharmaceuticals' Abiprubart Potential Despite Positive Industry Indicators
Kiniksa Pharmaceuticals to Present at Bank of America Securities 2024 Health Care Conference
PDF Version HAMILTON, Bermuda, May 07, 2024 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) today announced that management will participate in a fireside chat at the Bank of A
Express News | Wells Fargo Initiates Coverage On Kiniksa Pharmaceuticals With Overweight Rating, Announces Price Target of $34
Kiniksa Pharmaceuticals Is Maintained at Overweight by JP Morgan
Kiniksa Pharmaceuticals Is Maintained at Overweight by JP Morgan
Express News | JP Morgan Maintains Overweight on Kiniksa Pharmaceuticals, Raises Price Target to $30
Express News | Kiniksa Pharmaceuticals Ltd : JP Morgan Raises Target Price to $30 From $26
Comments
The share price rise is a fair reaction to the company's revenue growth. More gains could follow if the trend continues. Yet, consider the company's profitability and cash flow before investing.
Kiniksa Pharmaceuticals (NASDAQ:KNSA) Delivers Shareholders Respectable 66% Return Over 1 Year, Surging 4.7% in the Last Week AloneKiniksa Pharmaceuticals' low P/S ratio may be due to its forecast growth being lower than the industry. Shareholders accept this, conceding future revenue probably won't surprise positively. It's hard to see the share price rising strongly soon under these circumstances.
$Cellectar BioSciences(CLRB.US$ Phase 2
$Regenxbio(RGNX.US$ Phase 2
$Leap Therapeutics(LPTX.US$ Phase 2
$4D Molecular Therapeutics(FDMT.US$ Phase 2
$Adverum Biotechnologies(ADVM.US$ Phase 2
$Denali Therapeutics(DNLI.US$ Phase 2
$EyePoint Pharmaceuticals(EYPT.US$ Phase 2
$Xencor(XNCR.US$ Phase 2
$Harmony Biosciences(HRMY.US$ Phase 2
$Alnylam Pharmaceuticals(ALNY.US$ Phase 2
$Disc Medicine(IRON.US$ Phase 2
$Atea Pharmaceuticals(AVIR.US$ Phase 2
$Allakos(ALLK.US$ Phase 2...
$Regenxbio(RGNX.US$ Phase 2
$Leap Therapeutics(LPTX.US$ Phase 2
$4D Molecular Therapeutics(FDMT.US$ Phase 2
$Adverum Biotechnologies(ADVM.US$ Phase 2
$Denali Therapeutics(DNLI.US$ Phase 2
$EyePoint Pharmaceuticals(EYPT.US$ Phase 2
$Xencor(XNCR.US$ Phase 2
$Harmony Biosciences(HRMY.US$ Phase 2
$Alnylam Pharmaceuticals(ALNY.US$ Phase 2
$Disc Medicine(IRON.US$ Phase 2
$Atea Pharmaceuticals(AVIR.US$ Phase 2
$Allakos(ALLK.US$ Phase 2...
36
6
Kiniksa Pharmaceuticals' growing cash burn is offset by substantial cash reserves & signs of business growth. The firm can issue shares or borrow cheaply to fund further growth.
Read more